Singapore Clinical Trial: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety o... Read More

Singapore Clinical Trial: A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants with Early Alzheimer's Disease

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Effic... Read More

Singapore Clinical Trial: Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascend... Read More

Singapore Clinical Trial: A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant ... Read More

Singapore Clinical Trial: A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of mucus plugging and other lung imaging parameters in patients with chronic obstructive pulmonary disease

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A randomized, double-blind, placebo-controlled study to evaluate the effect of dupilumab on airway... Read More

Singapore Clinical Trial: CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safet... Read More

Singapore Clinical Trial: A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium-177 (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment

Singapore, June 24 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lu... Read More

One spurious drug sample from Assam detected in May 2026; probe underway: CDSCO report

New Delhi, June 24 -- As part of routine regulatory surveillance, the list of Not of Standard Quality (NSQ) and spurious drugs is being displayed on the Central Drugs Standard Control Organisation (CD... Read More

Maa Inti Bangaaram box office collection day 6: Samantha Ruth Prabhu film sees a midweek drop, collects rRs.r33 crore

India, June 24 -- Maa Inti Bangaaram box office collection day 6: Nandini Reddy and Samantha Ruth Prabhu's Maa Inti Bangaaram was released last week and debuted to good numbers at the box office. The ... Read More

The wait is over: Rockstar announces GTA VI price, pre-orders starts tomorrow- Here's how you can order

New Delhi, June 24 -- Rockstar Games has confirmed that "Grand Theft Auto VI" will cost $79.99 in the United States, making it one of the most expensive standard editions of a major video game to date... Read More

• ««
• «
• 9057
• 9058
• 9059
• 9060
• 9061
• 9062
• 9063
• 9064
• 9065
• 9066
• »
• »»